---
figid: PMC6046285__atm-06-12-253-f1
figtitle: Major signaling pathways activated through IGF-1R and EGF-R in adrenocortical
  carcinoma
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC6046285
filename: atm-06-12-253-f1.jpg
figlink: /pmc/articles/PMC6046285/figure/f1/
number: F1
caption: Major signaling pathways activated through IGF-1R and EGF-R in adrenocortical
  carcinoma. Activation of PI3K/AKT/mTOR and MAPK (Ras/Raf/MEK/ERK) intracellular
  pathway by either receptor results in cell survival, proliferation and tumor growth.
  Corresponding downstream molecules inhibitors (rosiglitazone, metformin, temsirolimus)
  and antibodies that target directly EGFR (erlotinib), IGF-1R (figitumumab, cetuximab)
  and IGF-1 (IMC-A12) are shown in this figure. IGF-2R lacks tyrosine kinase activity.
  EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; IGF-1, insulin-like
  growth factor; IGF-1R, insulin-like growth factor-1 receptor; IGFBP, insulin growth
  factor binding proteins; IRS, insulin receptor substrate; SHC, SHC adaptor protein;
  PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target
  of rapamycin; RAS, rat sarcoma viral oncogene homolog; RAF, rapidly accelerated
  fibrosarcoma; MEK, mitogen-activated protein kinase/extracellular signal-regulated
  kinase; ERK, extracellular signal-regulated kinase.
papertitle: The role of epithelial growth factors and insulin growth factors in the
  adrenal neoplasms.
reftext: Anna Angelousi, et al. Ann Transl Med. 2018 Jun;6(12):253.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9738124
figid_alias: PMC6046285__F1
figtype: Figure
redirect_from: /figures/PMC6046285__F1
ndex: 8a73d1f4-debe-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6046285__atm-06-12-253-f1.html
  '@type': Dataset
  description: Major signaling pathways activated through IGF-1R and EGF-R in adrenocortical
    carcinoma. Activation of PI3K/AKT/mTOR and MAPK (Ras/Raf/MEK/ERK) intracellular
    pathway by either receptor results in cell survival, proliferation and tumor growth.
    Corresponding downstream molecules inhibitors (rosiglitazone, metformin, temsirolimus)
    and antibodies that target directly EGFR (erlotinib), IGF-1R (figitumumab, cetuximab)
    and IGF-1 (IMC-A12) are shown in this figure. IGF-2R lacks tyrosine kinase activity.
    EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; IGF-1, insulin-like
    growth factor; IGF-1R, insulin-like growth factor-1 receptor; IGFBP, insulin growth
    factor binding proteins; IRS, insulin receptor substrate; SHC, SHC adaptor protein;
    PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target
    of rapamycin; RAS, rat sarcoma viral oncogene homolog; RAF, rapidly accelerated
    fibrosarcoma; MEK, mitogen-activated protein kinase/extracellular signal-regulated
    kinase; ERK, extracellular signal-regulated kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGFBP1
  - IGFBP2
  - IGFBP3
  - IGFBP4
  - IGFBP5
  - IGFBP6
  - IGFBP7
  - IGF2
  - EGF
  - IGF1
  - IGF1R
  - EGFR
  - IGF2R
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - WARS1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - Egfr
  - Shc
  - IRSp53
  - IleRS
  - chico
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Akt
  - Erk7
  - rl
  - Mtor
  - Tor
  - anon-70Dc
  - LanB2
  - anon-70Db
  - Dsor1
  - Mtk
  - Erlotinib
  - IMC
  - tyrosine
  - Rosiglitazone
  - Temsirolimus
  - Metformin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
